TCL1 peptides for immunotherapy have recently been patented (patent WO 2013075105 A3); they bind to MHC I (HLA-A2) on tumor cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells (34). The gene discussed is TCL1A; the disease is neoplasm.